Clonality and Antimicrobial Susceptibility of Burkholderia cepacia complex Isolates Collected from Cystic Fibrosis Patients during 1998-2013 in Bern, Switzerland.
For the first time, we analyzed the clonality and susceptibility of Burkholderia cepacia complex isolates (n=55) collected during 1998-2013 from 44 Swiss cystic fibrosis (CF)-patients. B. cenocepacia (n=28) and B. multivorans (n=14) were mainly of sequence type (ST) 833 and ST874, respectively; B. contaminans isolates were of ST102. Overall, the following MIC50/90s (mg/l) were obtained: piperacillin/tazobactam (≤ 4/≥ 128), ticarcillin/clavulanate (≥ 256/≥256), ceftazidime (2/≥ 32), aztreonam (16/≥ 32), meropenem (2/8), tobramycin (8/≥ 16), minocycline (≤ 1/16), levofloxacin (≤ 0.5/≥ 16), and trimethoprim/sulfamethoxazole (≤ 0.5/4). This is the first survey providing information on the clonality of Bcc detected in Switzerland. Species identification and antimicrobial susceptibility tests should always be routinely performed to adapt more targeted therapies.
Institute for Infectious Diseases, Faculty of Medicine, University of Bern, Bern, Switzerland.
Agnese
A
Lupo
Institute for Infectious Diseases, Faculty of Medicine, University of Bern, Bern, Switzerland.
Enver
E
Isis
Institute for Infectious Diseases, Faculty of Medicine, University of Bern, Bern, Switzerland.
Regula
R
Tinguely
Institute for Infectious Diseases, Faculty of Medicine, University of Bern, Bern, Switzerland.
Andrea
A
Endimiani
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D042602:Burkholderia cepacia complex / Q000145:classification / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification*; D003550:Cystic Fibrosis / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D013557:Switzerland
D000900:Anti-Bacterial Agents
Bcc; Burkholderia; Clonality; Cystic fibrosis; MIC; MLST